NRx Pharmaceuticals Receives FDA Approval for Generic Ketamine Injection
NRx Pharmaceuticals (NRXP) shares rose over 15% in premarket trading following the U.S. Food and Drug Administration's approval of its generic ketamine injection. The approval is granted via an abbreviated new drug application, marking a significant regulatory milestone for the company. The introduction of this generic version aims to address existing supply constraints within the United States for ketamine, which is widely utilized in pain management and anesthesia therapies. This development positions NRx Pharmaceuticals to enter a competitive market segment focused on essential anesthetic medications.
Tickers: $NRXP
Topics: FDA approval generic drug ketamine injection stock price movement